Preview

Russian Journal of Cardiology

Advanced search

IMPACT OF NICORANDIL IN ANGINA: SUBGROUP ANALYSES

Abstract

Aims: IONA (impact of nicorandil in angina) is a randomised, double blind, placebo controlled trial of nicorandil, with a target dose of 20 mg twice daily. The consistency of benefits seen in subgroups is reported. Methods: The primary composite end point of the study was coronary heart disease death, non-fatal myocardial infarction, or unplanned hospitalisation for cardiac chest pain. Subgroups were defined using baseline characteristics including, age, sex, histories of smoking, diabetes, hypertension, myocardial infarction, revascularisation, anginal status, anti-anginal treatment, other cardiovascular drugs, and an overall assessment of risk. Results: A total of 5126 patients were randomised to receive nicorandil or identical placebo in addition to standard anti-anginal treatment. Overall, nicorandil reduced the incidence of the primary end point from 15.5% to 13.1% (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.72 to 0.97; p = 0.014). There was no evidence of significant heterogeneity of benefit across all subgroups studied. The absolute risk reduction was greatest and the numbers needed to treat to prevent one event was lowest in subjects at greatest risk. Conclusions: The IONA study demonstrates a significant improvement in outcome by nicorandil treatment across a broad range of patients with stable angina. 

About the Author

IONA Study Group



References

1. Tunstall-Pedoe H. Angina pectoris: epidemiology and risk factors// Eur Heart J 1985;6:1–5.

2. Gandhi MM. Clinical epidemiology of coronary heart disease in the UK// Br J Hosp Med 1997;58:23–7.

3. Simon S, Niamh M, Andrew W, et al. The current cost of angina pectoris to the National Health Service in the UK// Heart 2003;89:848–53.

4. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients// BMJ 1994;308:81–106.

5. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting- enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients// N Engl J Med 2000;342:145–53.

6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S)// Lancet 1994;344:1383–9.

7. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels// N Engl J Med 1998;339:1349–57.

8. Rubins HB, Sander JR, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol// N Engl J Med 1999;341:410–8.

9. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial// Lancet 2002;359:1269–75.

10. Chibana T, Nagamine F, Sunagawa R, et al. Comparison of acute hemodynamic and coronary vasodilating effects between nicorandil and glyceryl trinitrate// Arzneim-Forsh/Drug Res 1991;41:6:591–4.

11. Treese N, Erbel R, Meyer J. Acute hemodynamic effects of nicorandil in coronary artery disease. J Cardiovas Pharmacol 1992;20: S3:52–6.

12. Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview// J Cardiovas Pharmacol 1987;10: S1–9.

13. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators// J Cardiol 1989;63:18–24J.

14. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients// J Cardiovasc Pharm 1992;20: S74–81.

15. Di Somma S, Liguori V, Verdecchia P, et al. A double-blind comparison of nicorandil and metoprolol in patients with effort stable angina// Cardiovasc Drugs Ther 1993;7:119–23.

16. Swan Study Group. Comparison of the antiischaemic and antianginal effect of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study// J Clin Basic Cardiol 1999;2:213–7.

17. Patel DJ, Purcell J, Fox KM. Cardioprotection by opening of the KATP channel in unstable angina// Eur Heart J 1999;20:51–7.

18. Tomai F, Crea F, Gaspardone A, et al. Mechanisms of cardiac pain during coronary angioplasty// J Am Coll Cardiol 1993;22:1892–6.

19. Yellon DF, Alkulaifi AM, Pugsley WB. Preconditioning the human myocardium// Lancet 1993;342:276–7.

20. Jenkins DP, Pugsley WB, Alkhulaifi AM, et al. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary bypass surgery// Heart 1997;77:314–8.

21. IONA Study Group. Impact of nicorandil in angina (IONA): design, methodology and management// Heart 2001;85: E9.


Review

For citations:


Study Group I. IMPACT OF NICORANDIL IN ANGINA: SUBGROUP ANALYSES. Russian Journal of Cardiology. 2010;(4):44-48. (In Russ.)

Views: 736


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)